A Single-center, Randomized, Open-label Pharmacokinetic Study of Famitinib Malate Capsules in Healthy Subjects
Latest Information Update: 12 Jun 2023
At a glance
- Drugs Famitinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 06 Jun 2023 Status changed from active, no longer recruiting to completed.
- 09 Oct 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 22 Sep 2021 New trial record